Long term proliferation assays also confirmed that combination therapy using BET inhibitor along with either BRAF or ERK signaling efficiently prevented growth of tumor cells carrying mutation of FBXW7 (Fig. 5j). The gene discussed is BRAF; the disease is neoplasm.